• Karl Herrup, Maria C Carrillo, Dale Schenk, Angela Cacace, Susan Desanti, Robert Fremeau, Ratan Bhat, Marcie Glicksman, Patrick May, Russell Swerdlow, Linda J Van Eldik, Lisa J Bain, and Samantha Budd.
• Hong Kong University of Science and Technology, Division of Biology Life Science, Hong Kong.
• Alzheimers Dement. 2013 Jul 1; 9 (4): 452-458.e1.

AbstractFor decades, researchers have focused primarily on a pathway initiated by amyloid beta aggregation, amyloid deposition, and accumulation in the brain as the key mechanism underlying the disease and the most important treatment target. However, evidence increasingly suggests that amyloid is deposited early during the course of disease, even prior to the onset of clinical symptoms. Thus, targeting amyloid in patients with mild to moderate Alzheimer's disease (AD), as past failed clinical trials have done, may be insufficient to halt further disease progression. Scientists are investigating other molecular and cellular pathways and processes that contribute to AD pathogenesis. Thus, the Alzheimer's Association's Research Roundtable convened a meeting in April 2012 to move beyond amyloid and explore AD as a complex multifactorial disease, with the goal of using a more inclusive perspective to identify novel treatment strategies.Copyright © 2013 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

52 keywords...

hide…